FDA Determines Regulatory Review Period for Aggrastat Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially announced its decision on the regulatory review period for the patent extension of Aggrastat, a human drug product, following a submission to the Commissioner of Patents and Trademarks, Department of Commerce.